F18 Sodium Flouride (NaF) is a highly sensitive bone-seeking PET Tracer. Its mechanism of uptake resembles that of Tc99 methylene diphosphonate (MDP), but with better pharmacokinetics than MDP. The pharmacokinetics of NaF, together with the morphological information from CT and functional information from PET enables better characterization of bone-lesions and bone-metastases. In this testimonial, physicians at Decatur Memorial Hospital share their experiences in incorporating F18 PET bone scan into their clinical practice. #GEHealthcare #GeneralElectric
Subscribe to GE Healthcare: https://www.youtube.com/channel/UC04R4GsgwjtoI28q7F3YrLw?sub_confirmation=1
Learn more about GE Healthcare
About GE Healthcare:
GE Healthcare is the $19 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services. With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, the company helps improve outcomes more efficiently for patients, healthcare providers, researchers and life sciences companies around the world.